Patented Medicine Prices Review Board Will Hear Evidence Regarding Alleged Breach of Reporting Requirements for Acne Drugs
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 09/22/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (the Board) will hold a public hearing with respect to allegations that Galderma Canada Inc. failed to provide Board Staff with the pricing and sales information required under section 80 of the Patent Act and sections 3 and 4 of the Patented Medicines Regulations. This proceeding relates to the medicines sold under the brand names Differin, Differin XP, TactuPump, and TactuPump Forte, which are generally indicated for the treatment of acne.
The public hearing is scheduled to take place from 10:00 a.m. to 4:00 p.m. (EST) from September 26 to September 27, 2016 at the following location:
The purpose of the hearing is to receive evidence and argument of Board Staff and Galderma Canada Inc. regarding allegations that Galderma Canada Inc. is in breach of its reporting requirements.
Quick Facts
Related Products
Additional Links
(Justice Canada)
(Justice Canada)
(Patented Medicine Prices Review Board)
Follow us on Twitter:
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
TTY (telecommunications device for the hearing impaired)
613-957-4373
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2016 - 12:00 Uhr
Sprache: Deutsch
News-ID 1459809
Anzahl Zeichen: 3913
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 552 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patented Medicine Prices Review Board Will Hear Evidence Regarding Alleged Breach of Reporting Requirements for Acne Drugs
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
